OncRef

Clinical Trial: NCT05601973

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:ETOP IBCSG Partners Foundation
Information Provided By:ETOP IBCSG Partners Foundation
Last Update Posted:2026-11-12

Study Overview

Brief Summary

AMAZE-lung is a multicenter single-arm phase II trial. The protocol treatment consists of amivantamab, lazertinib and bevacizumab (Zirabev®), given in a three-weekly regimen. The primary objective of the trial is to assess the efficacy of amivantamab and bevacizumab added to continued treatment with the third-generation EGFR-TKI lazertinib, in patients with EGFR-mutant advanced NSCLC, who have been previously treated with a third-generation EGFR-TKI in order to provide data on treatment effect and sample size required for a future phase III trial.

In addition, the safety of the treatment combination will be evaluated.

Official Title

A Multicentre Single-arm Phase II Trial of Amivantamab, Lazertinib Plus Bevacizumab in Patients With EGFR-mutant Advanced NSCLC With Progression on Previous Third-generation EGFR-TKI

Conditions

Non Small Cell Lung Cancer

Intervention / Treatment

  • Drug: Amivantamab
  • Drug: Lazertinib
  • Drug: Zirabev

Other Study ID Numbers

  • ETOP 18-21
  • 2021-002337-42

Start Date (Actual)

2023-03-27

Primary Completion Date (Actual)

2024-08-24

Study Completion Date (Estimated)

2027-04

Enrollment (Estimated)

60

Study Type

Interventional

Phase

Phase 2